Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.26% to $470.36 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.16% ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive ...

Vertex Pharmaceuticals (VRTX) closed at $476.37 in the latest trading session, marking a -0.28% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.27%.

At the American Society of Nephrology’s Kidney Week Congress last week, Biogen and Vertex Pharmaceuticals unveiled mid-stage data for their respective IgA nephropathy programs, touting strong clinical ...

As of October 28, 2024, Vertex Pharmaceuticals Incorporated had a $123.0 billion market capitalization, putting it in the 98th percentile of companies in the Biotechnology industry. Vertex ...

That includes, apparently, launching three-pointers with his heels on the logo. Watch video of Wembanyama ripping a ridiculously deep pull-up three here: Wembanyama is obviously on his way to ...

At the heart of this biotech boom lies Vertex Pharmaceuticals, a trailblazer that has played a pivotal role in transforming medical landscapes and reshaping patient lives. From groundbreaking ...

BOSTON - Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ:VRTX) has released new data demonstrating significant progress in its clinical trials for kidney diseases, including IgA ...

pharmaceuticals, investment, and patient advocacy. A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that makers and marketers of prescription opioid ...

So when a business like Vertex Pharmaceuticals (NASDAQ: VRTX) releases some new data on a potential blockbuster that could be just a few months away from being approved for sale, it's a big ...